IN-1130
目录号: PL11854 纯度: ≥99%
CAS No. :868612-83-3
商品编号 规格 价格 会员价 是否有货 数量
PL11854-5mg 5mg ¥1236.36 请登录
PL11854-10mg 10mg ¥2101.82 请登录
PL11854-25mg 25mg ¥4327.27 请登录
PL11854-50mg 50mg ¥6800.00 请登录
PL11854-100mg 100mg ¥11745.45 请登录
PL11854-200mg 200mg 询价 询价
PL11854-500mg 500mg 询价 询价
PL11854-10mM*1mLinDMSO 10mM*1mLinDMSO ¥1360.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
IN-1130
中文别名
3-[[5-(6-methylpyridin-2-yl)-4-quinoxalin-6-yl-1H-imidazol-2-yl]methyl]benzamide
英文名称
IN-1130
英文别名
3-[[5-(6-Methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl]methyl]-benzamide;IN 1130;IN-1130
Cas No.
868612-83-3
分子式
C25H20N6O
分子量
420.47
包装储存
Powder -20°C 3 years;4°C 2 years
产品详情
N-1130 是一种高度选择性的转化生长因子-β I 型受体激酶 (ALK5) 抑制剂,对 ALK5 介导的 Smad3 磷酸化的 IC50 为 5.3 nM。IN-1130 抑制酪蛋白的 ALK5 磷酸化 (IC50=36 nM),抑制 p38α 丝裂原活化的蛋白激酶 (IC50=4.3 μM)。IN-1130 可抑制阻塞性肾病中的肾纤维化,阻止乳腺癌的肺转移。
生物活性
IN-1130 is a highly selective transforming growth factor-β type I receptor kinase (ALK5) inhibitor with an IC 50 of 5.3 nM for ALK5-mediated Smad3 phosphorylation. IN-1130 inhibits ALK5 phosphorylation of casein (IC 50 =36 nM) and p38α mitogen-activated protein kinase (IC 50 =4.3 μM). IN-1130 suppresses renal fibrosis in obstructive nephropathy and blocks breast cancer lung metastasis.
性状
Solid
IC50 & Target[1][2]
ALK5
体外研究(In Vitro)
IN-1130 (0.5, 1 μM; for 2 hours) inhibits TGF-β-stimulated Smad2 phosphorylation and subsequent nuclear translocation in HepG2 and 4T1 cells.
IN-1130 (1 μM; for 72 hours) restores the TGF-β-mediated decrease in E-cadherin protein expression. IN-1130 (1 μM; for 72 hours) inhibits TGF-β-induced MMPs mRNA expression and the gelatinolytic activity of secreted MMPs in MCF10A cells.
IN-1130 (1 μM; pretreated for 30 min) inhibits TGF-β-induced MDA-MB-231 cells, NMuMG, and MCF10A cells mobility and invasion.
has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
IN-1130 (10, 20 mg/kg/day; IP; for 7 and 14 days) reduces the extent of interstitial nephritis and fibrosis (arrowheads) with 10 mg/kg and significantly reduces or absent histopathological changes with 20 mg/kg in unilateral ureteral obstruction (UUO) rats.
IN-1130 (10, 20 mg/kg/day; for 14 days) dose-dependently decreases levels of TGF-β1 mRNA and suppresses phosphorylation of Smad2, α-SMA, myofibroblasts in rat UUO kidneys.
IN-1130 (40 mg/kg; IP; 3 times per week for 3 weeks) inhibits in vivo breast cancer metastasis to the lungs in MMTV/c-Neu mice (Eight-week-old female BALB/c mice).
has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
参考文献
[1]. Moon JA, et al. IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int. 2006 Oct;70(7):1234-43.
[2]. Park CY, et al. An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition. Cancer Lett. 2014 Aug 28;351(1):72-80.
溶解度数据
In Vitro: DMSO : 100 mg/mL (237.83 mM; Need ultrasonic)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2